Press Releases

La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results
Nov 25, 2019
SAN DIEGO , Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it
Read More →
La Jolla Pharmaceutical Company Announces Management Transition
Nov 25, 2019
SAN DIEGO , Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that
Read More →
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Progress
Nov 12, 2019
SAN DIEGO , Nov. 12, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company  (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced
Read More →
La Jolla Pharmaceutical Company to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Sep 05, 2019
SAN DIEGO , Sept. 05, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that
Read More →
La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)
Aug 29, 2019
SAN DIEGO , Aug. 29, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that
Read More →
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Progress
Aug 01, 2019
SAN DIEGO , Aug. 01, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced
Read More →
La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for the Treatment of Malaria
Jul 23, 2019
-Orphan Drug Designation Program offers potentially up to seven years of marketing exclusivity- -NDA Submission Planned for Fourth Quarter of 2019- SAN DIEGO , July 23, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and
Read More →
La Jolla Pharmaceutical Company Receives Positive CHMP Opinion for GIAPREZA™ (angiotensin II) for the Treatment of Refractory Hypotension in Adults with Septic or Other Distributive Shock
Jun 28, 2019
SAN DIEGO , June 28, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that
Read More →
La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis
Jun 06, 2019
- Treatment with LJPC-401 Resulted in Statistically Significant Reduction in Change in Transferrin Saturation (TSAT), the Primary Efficacy Endpoint of the Study, and Frequency of Phlebotomies, a Key Secondary Efficacy Endpoint of the Study - SAN DIEGO , June 06, 2019 (GLOBE NEWSWIRE) -- La Jolla
Read More →
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress
May 06, 2019
SAN DIEGO, CA - May 6, 2019 - La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for
Read More →
La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118 for the Treatment of Severe Malaria
Apr 24, 2019
-Designation offers potential for expedited development and review, and highlights the urgent need for additional treatment options for patients suffering from severe malaria- - NDA Planned for LJPC-0118 for Fourth Quarter of 2019 - SAN DIEGO , April 24, 2019 (GLOBE NEWSWIRE) -- La Jolla
Read More →
La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer
Mar 11, 2019
SAN DIEGO , March 11, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the
Read More →
La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference
Mar 07, 2019
SAN DIEGO , March 07, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that
Read More →
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives
Mar 04, 2019
SAN DIEGO , March 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced
Read More →
La Jolla Pharmaceutical Company to Release Fourth Quarter and Full Year 2018 Financial Results on March 4, 2019
Feb 25, 2019
SAN DIEGO , Feb. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it
Read More →
La Jolla Pharmaceutical Company Announces Data Presentations at the Society of Critical Care Medicine’s 48th Critical Care Congress
Feb 14, 2019
New Data on GIAPREZA™ (angiotensin II) to be Presented in Oral Sessions at the Society of Critical Care Medicine’s 48th Critical Care Congress SAN DIEGO , Feb. 14, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that there will be multiple presentations on
Read More →
La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives
Jan 07, 2019
- Fourth-Quarter 2018 Net Sales of GIAPREZA Were Approximately $4.2 Million , Up 20% from the Third Quarter of 2018 - - Full-Year 2019 Net Sales Guidance for GIAPREZA of $24 Million to $28 Million - - Decision on GIAPREZA MAA by EMA Expected in June of 2019 - - NDA Planned for New Investigational
Read More →
La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference
Jan 04, 2019
SAN DIEGO , Jan. 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that
Read More →